All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
JZP458 in ALL/LBL: Complete follow-up results from AALL1931 trial
|
The phase II/III ALL1931 trial (NCT04145531) assessed the efficacy and safety of JZP458, a recombinant Erwinia asparaginase, in children and adult patients with ALL or LBL who had developed sensitivity to Escherichia coli-derived asparaginases. The complete follow-up results from the trial were published in Blood Advances by Maese. The study evaluated the efficacy and safety of different doses of JZP458 administered MWF in 2 cohorts (IM and IV). The primary efficacy endpoint was safety and the proportion of patients achieving NSAA level of ≥0.1 IU/mL in the last 72 hours during Course 1 of IM JZP458.1 |
| Key learnings |
| The proportion of patients reaching the NSAA level of ≥0.1 IU/mL in the last 72 hours was 64% in the IM 25 mg/m², 91% in the IM 37.5 mg/m², 90% in the IM 25/25/50 mg/m² cohort, and 40% in the IV 25/25/50 mg/m² cohort. |
| The frequency of serious TRAEs was 29% and 48% in the IM and IV cohorts, respectively. |
| Treatment discontinuation was reported in the 23% and 56% of patients in the IM and IV cohorts due to TRAEs (mainly allergic reactions and pancreatitis). |
| The complete follow-up results from the ALL1931 trial support the use of JZP458 in patients with ALL/LBL who are hypersensitive to Escherichia coli-derived asparaginases. |
Abbreviations: ALL, acute lymphoblastic leukemia; IM intramuscular; IV, intravenous; LBL, lymphoblastic lymphoma; MWF, Monday/Wednesday/Friday; NSAA, nadir serum asparaginase activity; TRAE, treatment-related adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?
